louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02003456: Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging
Official title: Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Ischemic Heart Disease
Myocardial Infarction
Keywords: positron emission tomography
rubidium
myocardial perfusion imaging
viability
FDG
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2013-12-06
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Positron emission tomography (PET) scans can be used to evaluate whether parts of the heart muscle are alive but receiving inadequate blood supply. This study involves the use of two radiotracers that will measure whether heart muscle cell are alive and quantify the blood supply to the heart muscle.

Detailed description: Positron emission tomography (PET) scans can be used to evaluate whether parts of the heart muscle (myocardium) are alive but receiving inadequate blood supply. This information can be helpful in identifying the best course of treatment. This type of study involves the use of two radiotracers: rubidium-82 (to measure blood flow) and 18F-fluorodeoxyglucose or FDG (to measure whether heart muscle cells are alive). Currently, each of these radiotracers is imaged at separate times, several hours apart. The purpose of this study is to evaluate methods that could allow the entire study to be performed at one time.

Eligibility criteria: Inclusion Criteria:

1. 18 years of age or older
2. Patients referred for clinically indicated positron emission tomography (PET) viability assessment with rubidium-82 rest perfusion imaging and 18F-fluorodeoxyglucose (FDG) metabolic imaging.

Exclusion Criteria:

1. Need for stress perfusion imaging
2. Claustrophobia which would prevent positron emission tomography (PET) imaging.
3. Inability to lie flat with arms positioned next to the head for approximately 20 minutes.
4. Clinical instability such as uncontrolled, potentially life threatening arrhythmias or heart failure requiring mechanical support or infusions of inotropic or vasopressor agents.
5. Pregnancy

Primary outcomes:
measure: Equivalence of Images from Rest Rubidium-82 Perfusion PET Obtained Separately versus Simultaneously
timeFrame: 2 years
Secondary outcomes:
measure: Equivalence of Quantitative Estimates of Global Myocardial Blood Flow using Rubidium-82 Perfusion PET Obtained Separately versus Simultaneously
timeFrame: 2 years
measure: Equivalence of Images from FDG PET Obtained Separately versus Simultaneously
timeFrame: 2 Years
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan Hospital
state: Michigan
Study officials:
affiliation: University of Michigan Hospital
name: Venkatesh L. Murthy, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01401309: PET Respiratory Gating to Detect Hepatic Metastasis in Patients With Colon Cancer
Official title: Effects of Respiratory Gating on FDG/PET Detection of Hepatic Metastasis in Patients With Colon Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Colon Cancer
Lead sponsor: Southwestern Regional Medical Center
Sponsor class: OTHER
First posted: 2011-07-25
Enrollment: 81
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with colon cancer

Brief summary: This study is to examine if there is improved sensitivity in detecting hepatic lesions using respiratory gating and if there is an improvement in confidence defining lesions as benign or malignant.


Eligibility criteria: Inclusion Criteria:

* Patients with colon cancer
* 18 years or older
* Signed Informed Consent Form
* Blood Glucose of 200 or less prior to scan

Exclusion Criteria:

* Patients with known hepatic metastasis

Primary outcomes:
measure: Detecting
timeFrame: Jan 2011 - Nov 2011
Secondary outcomes:
Other outcomes:
Locations:
city: Tulsa
country: United States
facility: Cancer Treamtent Centers of America at Southwestern Regional Medical Center, Inc
state: Oklahoma
Study officials:
References:
Clinical trial NCT02089009: Comparison of Non-mydriatic Camera Systems in a Female Health Hospital
Official title: Comparison of Non-mydriatic Camera Systems for Screening and Follow-up Examinations -Focused on the Retinal Vessel Situation- in the Population of a Female Health Hospital
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Eye Diseases
Retina; Lesion
Optic Disc Structural Anomaly
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
Collaborators: name: Optomed
First posted: 2014-03-17
Enrollment: 214
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: 1. To compare quality and usability of images taken by two different camera-systems without dilating the pupil.
2. To compare the retinal vessel diameters based on the images of to different camera-systems.
3. To detect changes in retinal vessel diameters while pregnancy and after delivery.

Detailed description: 1. To compare quality and usability of images taken by two different camera-systems without dilating the pupil.

   Quality means in this content that images cover the planned region of interest and images should be sharp and good illuminated to see details for medical reading of retinal findings.
2. To compare the retinal vessel diameters based on the images of to different camera-systems.

   The diameters of arteries and veins are planned to be measured with an automated software algorithm. Are there differences in the calculated results between the two used camera devices?
3. To detect changes in retinal vessel diameters while pregnancy and after delivery.

Are there detectable changes of the retinal findings between the images taken before and after delivery (e.g. bleeding, edema, vessel tortuosity)

Eligibility criteria: Inclusion Criteria:

* written informed consent
* age \>18 years
* pregnancy (only group 2)

Exclusion Criteria:

* limited ability for agreement
* heavy tremble
* reduced general condition
* known epilepsy

Primary outcomes:
measure: Image Quality
timeFrame: 12 to 16 month
Secondary outcomes:
measure: Retinal Pathologies
timeFrame: 12 to 16 month
measure: Differences Perinatal
timeFrame: 12 to 16 month
Other outcomes:
Locations:
city: Reutlingen
country: Germany
facility: Female Health Hospital Reutlingen
state: BW
city: Tuebingen
country: Germany
facility: University Eye Hospital
state: BW
Study officials:
affiliation: University Hospital Tuebingen
name: Martin A Leitritz, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05518409: Immunohistochemical Study of Neurodegenerative Diseases
Official title: Immunohistochemical Study of Peripheral Blood Mononuclear Cells in Sporadic Alzheimer's Disease and Dementia With Lewy Body
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Alzheimer Disease
Lewy Body Disease
Neurodegenerative Diseases
Lead sponsor: First Affiliated Hospital of Zhejiang University
Sponsor class: OTHER
First posted: 2022-08-26
Enrollment: 100
Sex: ALL
Minimum age (years): 55
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The subject uses cytof to analyze PBMC of sporadic AD and DLB, which is used to reveal the differences in immune characteristics of the two diseases at the single-cell level, build immune models for specific diseases, and define these two neurodegenerative diseases with high precision from the level of molecular immunity. To provide basis for further study of the immunohistochemical differences between the two diseases, and provide objective support for clinical diagnosis and differential diagnosis.


Eligibility criteria: Inclusion Criteria:

1. AD inclusion criteria:

   a.Clinical diagnosis of Alzheimer's Disease
2. DLB inclusion criteria:

   1. Clinical diagnosis of Dementia with Lewy bodies

Exclusion Criteria:

1. Infectious diseases
2. autoimmune disease
3. heart failure
4. chronic obstructive pulmonary disease (COPD)
5. cancer
6. renal failure
7. recently major surgery
8. alcohol and / or drug abuse
9. disturbance of consciousness
10. clinical diagnosis of major depression disorder
11. clinical diagnosis of Anxiety disorder

Primary outcomes:
measure: Immunerepertorie
timeFrame: 1 year
measure: immunological Elastic-Net (iEN) model
timeFrame: 1 year
Secondary outcomes:
measure: Mini-mental State Examination（MMSE）
timeFrame: 1 year
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Department of Psychiatry, First Affiliated Hospital of Zhejiang University
state: Zhejiang
Study officials:
affiliation: Zhejiang University
name: Li YouMing
role: STUDY_CHAIR
References:
Clinical trial NCT00638209: Insulin Sensitivity of the Brain in Pathogenesis of Diabetes Mellitus Type 2
Official title: Insulin Sensitivity of the Brain in Pathogenesis of Diabetes Mellitus Typ 2
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Human Physiology of Energy Homeostasis
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
Collaborators: name: German Research Foundation
First posted: 2008-03-19
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of the study is to investigate whether insulin sensitivity of the human brain correlates with insulin sensitivity of the liver.


Eligibility criteria: Inclusion Criteria:

* Age 18-70 Risk factor(s) for type 2 diabetes (e.g. overweight, family history of diabetes)

Exclusion Criteria:

* Type 2 diabetes pregnancy acute or chronic diseases

Primary outcomes:
measure: Insulin effect on cortical function (spectral analysis)
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Tuebingen
country: Germany
facility: University Hospital Tuebingen, Internal Medicine IV
city: Tuebingen
country: Germany
facility: University Hospital Tuebingen
Study officials:
References:
Clinical trial NCT02550509: Changes in Echogenicity and Muscle Stiffness in Elastography After Botulinum Toxin Injection a Spastic Muscle
Official title: Changes in Echogenicity and Muscle Stiffness in Elastography After Botulinum Toxin Injection a Spastic Muscle - A Monocentric Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Stroke
Keywords: stroke
Botulinum toxin
Muscle alterations
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
First posted: 2015-09-15
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Muscle alterations and modifications passive biomechanical properties that occur on a spastic muscle contribute to functional disorders involved in spasticity. Botulinum toxin (TB) A is the reference treatment of the focused spasticity, and muscle source structural and biomechanical changes, very little studied in humans, especially since it is not one possibility of easily and reliably paraclinical assessment injections consequences.


Eligibility criteria: Inclusion Criteria:

* A first stroke older than nine months (acute phase and subacute stroke).
* Hemiplegia cerebral vascular following this stroke.
* Hemiplegia with an overall motor deficit plegic lower limb muscle testing level less than or equal to 3 and associating a localized spasticity lower plegic member, on the plantar flexors, assessed by the upper Ashworth Scale or equal to 1 with an injection of botulinum toxin indication of the sural triceps.
* written consent.

Exclusion Criteria:

* Old stroke with motor impairment of the lower limb in the chronic stage.
* Concomitant muscle disease (eg myopathy, myositis ...).
* Patients who already received a botulinum toxin injection into the gastrocnemius muscles.
* Subjects with defibrillator

Primary outcomes:
measure: Change in muscular trophism
timeFrame: from baseline to 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Saint-Etienne
country: France
facility: CHU Saint-Etienne
Study officials:
affiliation: CHU SAINT-ETIENNE
name: PAul Calmels, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02202109: Using CHWs or Mailing Self Sampling Home Tests to Increase Cervical Cancer Screening in South Florida
Official title: Addressing Cervical Cancer Disparity in South Florida: CBPR in Action
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cervical Cancer
Keywords: Screen
self-sampler
cervical, cancer
women
community health workers
Hispanic/ Latinas
Haitian
Focus of study is cervical cancer
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: Health Choice Network
name: Center for Haitian Studies
name: National Cancer Institute (NCI)
First posted: 2014-07-28
Enrollment: 602
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The study will test the significance of community health worker (CHW) participation by comparing self-sampling provided by a community health worker and self-sampling provided by mail. The study will enroll 700 participants in communities that lack access to medical care in South Florida.


Eligibility criteria: Inclusion Criteria:

* Women
* Haitian, Hispanic, or African American
* Ages 30-65 years
* Report not having had a pap smear in the last three years live in the cities of Miami/Little Haiti, Hialeah or unincorporated Southern Miami-Dade

Exclusion Criteria:

* Women who report having had a hysterectomy
* Women who have a history of cervical cancer
* Women who plan to move outside of Miami-Dade county during the next six months
* Women who are enrolled in any other cancer prevention/outreach related study
* Adults unable to consent
* Individuals who are not yet adults (infants, children, teenagers)
* Pregnant women
* Prisoners

Primary outcomes:
measure: Number of Participants Completing a Self-sampling Test
timeFrame: 2 to 6 months
Secondary outcomes:
measure: Proportion of Change in Cervical Cancer Knowledge Among Participants
timeFrame: Baseline, 6 months
measure: Proportion of Participants With a Change in Access to Care
timeFrame: Baseline, 6 months
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
Study officials:
affiliation: University of Miami
name: Erin Kobetz, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kobetz E, Seay J, Amofah A, Pierre L, Bispo JB, Trevil D, Gonzalez M, Poitevien M, Koru-Sengul T, Carrasquillo O. Mailed HPV self-sampling for cervical cancer screening among underserved minority women: study protocol for a randomized controlled trial. Trials. 2017 Jan 13;18(1):19. doi: 10.1186/s13063-016-1721-6.
Clinical trial NCT07021209: GT719 Injection for Recurrent/Refractory Antibody Mediated Systemic Immune Diseases
Official title: A Single-arm, Open-label, Phase I Clinical Study of GT719 Injection for Recurrent/Refractory Antibody Mediated Systemic Immune Diseases
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Neurological Disorder
Lead sponsor: Grit Biotechnology
Sponsor class: INDUSTRY
First posted: 2025-06-13
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune disorders.


Eligibility criteria: Inclusion Criteria:

* Voluntarily enrolled in the study, signed an informed consent form, willing and able to comply with the study protocol.
* Expected survival period\>12 weeks.
* Any previous systemic treatment must have undergone at least 4 weeks or 5 half lives (whichever is shorter) by the time the participant plans to receive the study treatment.

Exclusion Criteria:

* History of organ transplantation, splenectomy, and allogeneic or autologous stem cell transplantation.
* History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment, requiring systemic anticoagulant therapy.
* Received systemic corticosteroids within 7 days prior to GT719 infusion, except for inhaled corticosteroids

Primary outcomes:
measure: Incidence and severity of adversed events
timeFrame: 3 years
Secondary outcomes:
measure: Pharmacokinetics of GT719 cells
timeFrame: 3 years
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
state: Hubei
Study officials:
affiliation: Tongji Hospital
name: Wei Wang
role: PRINCIPAL_INVESTIGATOR
affiliation: Tongji Hospital
name: Daishi Tian
role: PRINCIPAL_INVESTIGATOR
affiliation: Tongji Hospital
name: Chuan Qin
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05160909: Evaluation of Surgical Positioning in Arthroscopic Shoulder Stabilization
Official title: The Effects of Surgical Positioning on Arthroscopic Shoulder Stabilization: A Prospective Comparison
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Shoulder Dislocation
Lead sponsor: Rothman Institute Orthopaedics
Sponsor class: OTHER
First posted: 2021-12-16
Enrollment: 556
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who undergo arthroscopic labral repair due to shoulder instability, with or without concomitant debridement.

Brief summary: The purpose of this study is to prospectively determine whether intra-operative factors, complications and post-operative outcomes differ between beach chair and lateral decubitus surgical positioning for patients receiving arthroscopic shoulder stabilization (anterior or posterior) due to shoulder instability.


Eligibility criteria: Inclusion Criteria:

-Any patient undergoing arthroscopic labral repair due to shoulder instability, with or without concomitant debridement.

Exclusion Criteria:

* Revision stabilization surgery
* No previous Bankart repairs, labral repairs, capsulorrhaphy, or Latarjet
* Multidirectional shoulder instability
* Concomitant rotator cuff repair, biceps tenodesis/tenotomy, HAGL repair
* Isolated SLAP repair/labral repair in association with mechanism other than -instability (eg: overhead athletes) open procedures for instability

Primary outcomes:
measure: Shoulder instability
timeFrame: 2 years
Secondary outcomes:
measure: Postoperative patient satisfaction
timeFrame: 2 years
measure: Postoperative patient satisfaction
timeFrame: 2 years
measure: Postoperative patient satisfaction
timeFrame: 2 years
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Rothman Orthopaedic Institute
state: Pennsylvania
Study officials:
References:
Clinical trial NCT06407609: Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
Official title: Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS Subjects With Small Bowel Dysbiosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Boswellia Serrata
Irritable Bowel Syndrome
Keywords: Bloating
Dysbiosis
Boswellia serrata
Curcuma longa
Irritable bowel syndrome
Microbiota
Phytosome
Lead sponsor: Azienda di Servizi alla Persona di Pavia
Sponsor class: OTHER
First posted: 2024-05-09
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Small bowel dysbiosis (SBD), is a frequent finding in subjects with irritable bowel syndrome (IBS). The formula-tion in sunflower lecithin (Phytosome) of Curcuma longa and Boswellia serrata demonstrated beneficial effects on intestinal microbiota. The aim of this study was to evaluate the effect of a lecithin-based delivery formulation of Curcuma longa and of Boswellia serrata extracts (CUBO), on SBD in IBS subjects.


Eligibility criteria: Inclusion Criteria:

* age ranging from 18 to 70 years;
* diagnosis of moderate IBS according to Rome IV criteria;
* dysbiosis of the small bowel, defined by increased urinary indican values with normal values of urinary skatole;
* evidence of abdominal bloating and abdominal pain

Exclusion Criteria:

* normal values of urinary indican or increased values of urinary skatole ;
* subjects who were already on a low FODMAP diet (LFD) or other dietary prescription, such as lactose or gluten free diet in the last 6 months;
* insulin-dependent diabetes or seafood, nuts or soy allergies ;
* positive history of symptomatic diverticular disease, celiac disease, inflammatory bowel disease or microscopic colitis;
* colonic or small bowel or gallbladder surgery ;
* severe vomiting or bloody diarrhea ;
* liver disease (defined as altered values of liver function tests) or severe renal disease (defined as serum creatinine \>1.5 mg/dL) or treatment with antibiotics, excluding those for topical use, within the last three months

Primary outcomes:
measure: Evaluate the effect of Lecithin formulation on small bowel dysbiosis
timeFrame: from baseline to 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Pavia
country: Italy
facility: Mariangela Rondanelli
state: PV
Study officials:
References:
Clinical trial NCT01225809: AD01 Follow up Extension Visit
Official title: Observational Follow-up Extension Study-visit to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE AD01 Applied During AFFiRiS001 in Patients With Alzheimer's Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Alzheimer´s Disease
Keywords: AD01 follow-up extension
Lead sponsor: Affiris AG
Sponsor class: INDUSTRY
First posted: 2010-10-21
Enrollment: 17
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients having participated in AFFiRiS 001 and AFF003 and having received ≥1 vaccination with AFFITOPE AD01

Brief summary: Patients who were vaccinated with AFFITOPE AD01 during AFFiRiS001 will undergo a long-term follow-up period to get more information regarding the safety profile of AFFITOPE AD01.


Eligibility criteria: Inclusion Criteria:

* Written informed consent signed and dated by the patient or the patient's legal representative and the caregiver.
* Patients having participated in AFFiRiS 001 and AFF003 and having received ≥1 vaccination with AFFITOPE AD01
* Availability of a partner/caregiver knowing the patient

Exclusion Criteria:

* Patients having received no vaccination with AFFITOPE AD01
* History of questionable compliance to visit schedule

Primary outcomes:
measure: Long term tolerability and safety of AFFITOPE AD01
timeFrame: One year.
Secondary outcomes:
Other outcomes:
Locations:
city: Wien
country: Austria
facility: Univ. Klinik für Neurologie
Study officials:
affiliation: Univ. Klinik für Neurologie
name: Peter Dal-Bianco, MD
role: PRINCIPAL_INVESTIGATOR
References: